Testing a new eye injection for diabetic macular edema
Treatments studied
Part of Eyes & vision, Hormones & metabolism clinical trials.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have diabetes (type 1 or 2).
- Your latest blood sugar test (HbA1c) must be 12% or lower.
- In the study eye, you have swelling in the center of the retina that is at least 325 micrometers thick, and your vision is between 20/50 and 20/200 (65 to 35 letters on an eye chart).
- You cannot have had any eye injections or implants (like anti-VEGF or steroid treatments) before joining (if you are in Parts 1 or 2 of the study).
- You cannot have uncontrolled high blood pressure, active eye inflammation, or a history of certain eye conditions like uveitis or severe diabetic retinopathy in the study eye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
This trial compares a new treatment (EYP-1901, given as an injection) to a standard injection (aflibercept) for people with diabetic macular edema. It aims to see which works better at reducing swelling and improving vision.
This Phase 3 study compares a new eye injection (RC28-E) with the standard treatment (aflibercept) for diabetic macular edema, which is swelling in the central retina that affects vision. It aims to see whether the new treatment works as well and is safe.
This trial tests a new eye injection called faricimab to treat diabetic macular edema (swelling in the back of the eye) in South Asian patients. The goal is to see how well it works, how long the effects last, and if it is safe.
This Phase 1 study tests the safety and early effectiveness of OCU200 eye injections in people with diabetic macular edema (DME) that affects the center of vision. It may help by reducing the eye swelling that blurs vision from diabetes.
This trial tests a gene therapy called RGX-314 for people with diabetic macular edema that affects the center of the vision. If you have had previous treatment and still have swelling, this study may be an option.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.